We have published an application note that presents a reliable and quick method using NanoPak- C All carbon columns for simultaneously determining Insulin Aspart and its phenolic preservatives in clinical formulations. This optimized HPLC method is suitable for routine analysis and quality control of Insulin Aspart in clinical formulations.
Insulin Aspart is a rapid-acting insulin medication used to manage diabetes mellitus, both type 1 and type 2. Phenol and meta-Cresol are phenolic preservatives commonly found in insulin aspart formulations. They act as antimicrobial agents, helping prevent bacteria and other microbes from growing in the insulin solution, which is crucial for maintaining sterility. Studies suggest they may also play a role in stabilizing the insulin molecule itself, especially at higher temperatures. On the other hand, some research suggests they might contribute to localized allergic reactions at the injection site.
HPLC analysis is essential for ensuring the quality, safety, and efficacy of Insulin Aspart medications. Separating Insulin Aspart from phenol and meta-Cresol using HPLC requires careful consideration of column selection, mobile phase optimization, and potential challenges due to their similar properties.
The NanoPak- C All carbon columns, a key component of our new method, offer a unique surface chemistry that exhibits a stronger affinity for hydrophobic compounds such as Insulin aspart and phenolic preservatives. This unique feature translates to better separation between these compounds and potential interfering substances in the sample matrix, making it an invaluable tool for your research.
We invite you to download this application note here.
Please email us at inquiry@millennialscientific.com, call us at 855 388 2800, or fill in our online form.
Comments